Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne HodgkinsonCelia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkeuven

    Research output: Contribution to journalArticlepeer-review

    128 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis'. Together they form a unique fingerprint.

    Medicine & Life Sciences